While a large number of HPK1 programs have identified lead HPK1 kinase inhibitors that can block HPK1 kinase activity with the half maximal inhibitory concentration IC50 values in the low nM concentration, there have been no published report of enhanced anti-tumor immunity that have been elicit by small molecule inhibitor of HPK1 to date. This evidence concerns the gene MAP4K1 and neoplasm.